SCHEMBL7328210

SCHEMBL7328210

COc1cc(C(F)(F)F)nn1-c1ccc(NC(=O)c2ccccc2F)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
THRB P10828 3/20 0.60
TP53 P04637 4/20 0.57
TRPC1 P48995 1/20 0.56
TRPC3 Q13507 1/20 0.56
STIM1 Q13586 1/20 0.56
ORAI1 Q96D31 1/20 0.56
CRACR2A Q9BSW2 4/20 0.56
POLB P06746 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
TLR8 Q9NR97 1/20 0.49
F10 P00742 1/20 0.49
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
HPGD P15428 1/20 0.48
ALDH1A1 P00352 1/20 0.48
MCL1 Q07820 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7316349 0.88 ORAI1 (0.54) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7327184 0.87 MAPT (0.55) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7320569 0.87 ORAI1 (0.75) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL14887700 0.86 CRACR2A (0.61) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7326834 0.85 ORAI1 (0.75) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7315926 0.84 ORAI1 (0.57) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7323552 0.83 ORAI1 (0.56) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7322310 0.81 KCNJ6 (0.52) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7325414 0.81 ORAI1 (0.56) MAPTSMN1; SMN2THRBTP53TRPC1
SCHEMBL7326362 0.81 CRACR2A (0.66) MAPTSMN1; SMN2THRBTP53TRPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010044445-A1 AZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES 2001-11-22 US claimed
EP-1068187-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 2001-01-17 EP claimed
WO-1999051580-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 1999-10-14 WO claimed
US-20010044445-A1 AZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES 2001-11-22 US disclosed
EP-1068187-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 2001-01-17 EP disclosed
WO-1999051580-A1 PYRAZOLE INHIBITORS OF CYTOKINE PRODUCTION ABBOTT LABORATORIES (US) 1999-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010044445-A1 AZOLE INHIBITORS OF CYTOKINE PRODUCTION IL5, IL2, IL4 MAPT 2674/4885SMN1; SMN2 4665/4885THRB 3730/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.